Every day, Global University Venturing rounds up investments from across the university innovation ecosystem in its deal net.
Ambagon Therapeutics, a US-based biotech developer using small molecules to unlock disordered protein targets, launched last week with $85m in series A funding to commercialise research conducted at University of California, San Francisco and Eindhoven University of Technology. The round’s backers included Merck and Co’s MRL Ventures Fund and fellow pharmaceutical firm AbbVie’s corporate VC unit, AbbVie Ventures. It was led by Nextech Invest and also featured Surveyor Capital as well as RA Capital Management, Droia Ventures, Inkef Capital and…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
